Mountain Crest Acquisition II stockholders voted in favor of of the proposed business combination with Better Therapeutics.
Neither the news release nor a subsequent 8-K filing mentioned redemptions, if any. The SPAC dipped below $10 in the two days leading up to the redemption deadline.
When announced in April, the transaction valued Better Therapeutics at a pro forma fully diluted enterprise value of approximately $187 million.
The transaction is expected to close today. Better Therapeutics is expected to begin trading tomorrow on the Nasdaq under BTTX.
Better Therapeutics is developing a novel form of cognitive behavioral therapy to address the root causes of cardiometabolic diseases. Read more.
